ABOUT C.S. GROUP
Cordyceps Sunshine Biotech Holdings Co., Ltd. (“C.S. Group”) is a Cayman Islands–incorporated biotechnology company specializing in rare and high-value medicinal fungi. Built on innovative agricultural biotechnology, we focus on the cultivation and scalable production of some of the world’s most scarce functional fungi.
We operate dedicated Antrodia cinnamomea cultivation and production facilities in Taiwan and Mainland China, providing the market with safe, reliable, and effective Antrodia raw materials. In addition, we have established Taiwan’s largest Antrodia retail chain, further strengthening our leadership in the category.
In 2025, we achieved the successful isolation and purification of Antcin A, a rare and highly valuable bioactive compound from Taiwanofungus camphoratus (Antrodia cinnamomea), and established it as our proprietary lead molecule, TFA-01.
As the world’s first biopharmaceutical company founded on TFA-01, we are building a next-generation non-steroidal anti-inflammatory molecular platform designed to address the global multi-billion-dollar corticosteroid market through innovative steroid-sparing therapies.
Taiwanofungus camphoratus Cultivation
After years of development and with hundreds of millions invested over several years, we upgraded and optimized our process across three critical dimensions—strain selection, cultivation substrate, and analytical testing. The result is TF-15 Antrodia cinnamomea (Taiwanofungus Antcin A 1500 ppm), a breakthrough product that matches wild-grown Antrodia in appearance, composition, and aroma. The key differentiator is its high concentration of Antcin A, reaching 1500 ppm. TF-15 is safe and non-toxic, delivers stable and scalable output, and offers consistent, controllable quality you can rely on.
Development of Novel Fixed-Dose Combination (FDC) Animal Drugs
Our research has revealed that beyond its proven efficacy for human consumption, Taiwanofungus camphoratus holds immense therapeutic potential in the field of pet healthcare. To align with international PIC/S GMP pharmaceutical standards and further explore the pharmacological applications of its bioactive compounds, we invested nearly 100 million TWD in 2025 to establish a dedicated Antcin A Drug Research Laboratory.
Featured Projects
"Mankind has spent thousands of years searching for the secret to longevity. Our findings suggest that the definitive solution resides in these precious fungi."
Companion Animal Drug Development
Dietary Supplements
Holistic Pet Food
Patents And Technology
Management Team
Products And Channels
Latest News
C.S. Group Achieves Major Breakthrough in Veterinary Drug Development; Completes Phase I Clinical Trials of Antcin-Based Novel Drug, Aiming for Taiwan’s First Regulatory Approval.
C.S. Group, Taiwan’s largest specialized Taiwanofungus Camphoratus retail chain, hosted the ‘Antcin A Veterinary Drug Phase I Trials &…
A Breakthrough in Taiwanofungus Camphoratus: Applying Fungal Research to Pet Wellness.
Professional Collaboration and Quality Assurance: Partnering with veterinary networks to provide science-based wellness recommendations. We have established rigorous quality…
From the ‘Ruby of the Forest’ to Scientific Testing Standards: C.S. Group Redefines the Industrial Value of Taiwanofungus Camphoratus.
C.S. Group is redefining the Taiwanofungus Camphoratus landscape by transitioning the species from a traditional supplement to a…
Commercialization Potential Enabled by a Molecular Platform Strategy
Pet Drug Development Data Assets
Comprehensive preclinical safety, efficacy, and standardized manufacturing datasets establish the scientific foundation of our platform and support future product development and commercialization.
API Out-Licensing
Out-licensing TFA-01 as an Active Pharmaceutical Ingredient (API) to pharmaceutical companies worldwide, generating early-stage cash flow while establishing strategic collaborations for future growth.
Human Therapeutics Development
Utilizing robust animal model data to support IND submissions and accelerate clinical development programs targeting osteoarthritis and chronic inflammatory diseases in humans.
Take action now and experience the transformative wellness power of rare, natural fungi for yourself.
Contact us for an immediate follow-up from our team.